Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple sleep test replace the lab for MSA patients?

NCT ID NCT00743561

Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a portable sleep monitor used during a short hospital stay can accurately diagnose sleep apnea in people with multiple system atrophy (MSA), compared to the standard overnight lab test. Thirty adults with probable MSA took part. The goal was to see if the simpler test could replace the more complex one, making diagnosis easier for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Start date

Jun 2008

Finished

Jan 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of "probable" MSA according to current consensus criteria (Gilman et al. 1999, PMID 10223419) * Age 30-80 years * Oral informed consent of patient or representative * Patient requiring hospitalization in a neurology unit Exclusion Criteria: * Progressive cancer * Significant cognitive impairment (MMSE\<24) * Sleep apnea * Respiratory disorder * Less than one year since previous polysomnography or ambulatory polygraphy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple system atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy Sleep apnea syndromes

Contacts and locations

Locations

  • CHU de Bordeaux - Hôpital Pellegrin

    Bordeaux, 33096, France

  • CHU de Bordeaux - Hôpital du Haut-Lévêque - Département de Neurologie - Centre de référence nationale maladie rare AMS

    Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.